Tenderwize
Zurück zur Suche

Non-exclusive discount agreement for Tamsulosin and Dutasterid

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 218 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tamsulosin und Dutasterid, ATC G04CA52

55/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

55 / 100

Komplexität

40 / 100

Risikofaktoren

Non-exclusive contracts may be terminated early if the buyer initiates exclusive tenders; no guaranteed revenue.

Paper submission increases risk of delays or loss; must meet strict receipt deadlines.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for pharmaceuticals with active substance Tamsulosin and Dutasterid (ATC G04CA52)
  • Exclusion of paediatric medicines according to BfArM list per §35 Abs. 5a SGB V
Vollständige Zusammenfassung anzeigen

The tender is an open-house non-exclusive discount agreement for pharmaceutical products containing Tamsulosin and Dutasterid (ATC G04CA52), offered by AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse. All eligible pharmaceutical companies can join on equal terms. Contracts run for a maximum of 24 months, with the earliest start on 01.06.2025 and latest end on 31.05.2027. Enrollment is possible monthly, subject to a two-month lead time. The notice explicitly states it is not a public procurement under EU directives but is published for transparency. No estimated value is provided.

Risiken

Non-exclusive contracts may be terminated early if the buyer initiates exclusive tenders; no guaranteed revenue.

Paper submission increases risk of delays or loss; must meet strict receipt deadlines.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Pharmaceutical companies must hold a valid marketing authorization for the relevant products in Germany
  • Products must be listed as marketable in the Lauer-Taxe or provide evidence via AMIce database extracts

Administrative

  • Submission of signed contract documents by the appropriate deadline (first deadline 30.04.2025 for start 01.06.2025; subsequent deadlines are 2 months before intended start date)

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No explicit award criteria; all participants are accepted under uniform terms (open-house).

Auftraggeber

Lose (1)

LOT-0001

Non-exclusive discount agreement for Tamsulosin and Dutasterid

Open-house model for non-exclusive discount agreements on pharmaceuticals with active substances Tamsulosin and Dutasterid. All qualified pharmaceutical companies can participate. Terms are uniform; no individual negotiations. Contracts end automatically if exclusive agreements replace them.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No explicit award criteria; all participants are accepted under uniform terms (open-house).

Frist

Deadline Mar 31, 2027

Vergabedetails

Veröffentlichungsdatum
10 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
236184-2025

Dokumente (1)

Ähnliche Ausschreibungen